Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. (AVBP) Stock Overview

Explore ArriVent BioPharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

AVBP●NASDAQ
HealthcareBiotechnology
$29.74
$0.84(2.91%)
U.S. Market opens in 2h 49m

ArriVent BioPharma, Inc. (AVBP)

Meyka AI Score

Z

Key Financials

Market Cap1.4B
P/E Ratio-8.10
EPS (TTM)$-3.47
ROE-0.50%
Fundamental Analysis

AI Price Forecasts

1 Month$30.86
3 Months$37.39
1 Year Target$33.41

AVBP Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of ArriVent BioPharma, Inc. (NASDAQ: AVBP) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, ArriVent BioPharma, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of AVBP on the NASDAQ shows an RSI of 50.49, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $33.41 for the NASDAQ listing.

Key metrics behind ArriVent BioPharma, Inc.'s NASDAQ-traded stock include a P/E ratio of -8.10 and a market capitalization of 1.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of AVBP on the NASDAQ.

Price Performance (NASDAQ: AVBP)

1-Day Change
2.91%
5-Day Change
5.65%
1-Month Change
2.13%
3-Month Change
-9.05%
6-Month Change
35.06%
Year-to-Date (YTD) Change
47.81%
1-Year Change
59.72%
3-Year Change
48.70%
5-Year Change
48.70%
All-Time (Max) Change
48.70%

Contact Information

https://arrivent.com
628-277-4836
18 Campus Boulevard Suite 100, Newtown Square, PA, 19073

Company Facts

770 Employees
IPO DateJan 26, 2024
CountryUS
Actively Trading

Frequently Asked Questions